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INTRODUCTION 
The recent spread of very sensitive P-hCG assays and assisted reproductive 
technologies has revealed how high the rate of very early and preclinical abortions 
This has made clear that implantation is the true limiting factor of human 
reproduction. Implantation necessarily implies a specific immunologic interaction 
between the embryo and the mother: many immune modifications have been 
claimed in recent literature to explain the tolerance of the fetal allograft .3,4 This 
immune approach has given a theoretical basis to different therapeutic strategies 
for recurrent abortions involving either a partner or donor leukocyte active immuni- 
~a t ion ’ .~  or passive immunization by intravenous immunoglobulins (WIG)’ to 
prevent implantation failures.* 
This work, based on a previous preliminary investigation,’ aims to verify the 
effectiveness of IVIG treatment in the prevention of implantation failures in an 
open randomized comparative study versus placebo and to identify possible param- 
eters predictive of conditions liable to be successfully treated by this protocol. 
MATERIAL AND METHODS 
Patients 
The patients were thirty-nine women with: a) two or more very early abortions 
(less than 8 weeks) or biochemical pregnancies (marked by two consecutive in- 
creases in @-hCG levels without USG evidence of gestational sac); and b) three or 
more failed attempts of embryo transfer after IVF, replacing at least three embryos. 
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TABLE 1. Clinical Outcomea 
Cases PR IR AR 
Group A 18 6/18 8/45 1 I6 
Group B 21 4121 4/61 215 
(33.3%) (17.7%) (16.6%) 
(19.1%) (6.5%) (40.0%) 
u p  < 0.05 (Fisher’s Exact Test). 
Protocol and Study Design 
Eighteen patients were randomized in the IVIG treatment group (group A) and 
21 in the placebo arm (group B). All patients underwent a superovulation protocol, 
which included ovarian desensitization by GnRH analogs. Before gonadotropin 
stimulation, patients received the first administration of 200 ml of immunoglobulin 
concentrate (20 g, group A) or placebo (group B). A second administration was 
given when P-hCG was positive and, then, every three weeks up to the 20th week 
of gestation. Following the treatment all patients were monitored for changes in 
a) serum profile of immunoglobulins, b) unidirectional “mixed lymphocyte cul- 
ture” (MFC) (to detect possible blocking factors5), and c) trophoblast penetration 
through a three-dimensional support. The latter test was performed in uitro using 
a specific endometrial primary cell culture, according to a procedure originally 
described by us, named “double tube microinvasion test” and detailed in Refer- 
ence 10. In brief, the test consists in matching primary endometrial cell culture 
(from endometrial biopsies from the previous cycle stimulated in the same way 
as at the time of implantation), with a choriocarcinoma cell line (JEG-3) in two 
separate Millipore tubes (5 mm diameter). After 48 hours culture in suspension 
in Ham F-10 supplemented with 5% FBS to allow cells to adhere to walls and to 
produce extracellular matrix, the two tubes were put head by head and held 
together with a cuff. Five days later, a number of trophoblast cells (identified by 
MoAb PKKl  for cytokeratine) migrated into the endometrium: the entity of this 
migration and the number of migrated cells was finally measured. 
RESULTS AND DISCUSSION 
Clinical outcome in group A (IVIG) and B (placebo) is reported in TABLE 1. 
It may be seen that while the pregnancy rate (PR) was not statistically significant 
(33.3 vs 19. l) ,  the implantation rate (IR) in the IVIG group was remarkably higher 
( p  < 0.05) as compared to the placebo group (17.7% vs 6.5%). The abortion 
rate (AR) was 16.6% in group A and 40.0% in the placebo group. At To the 
immunoglobulin serum profile and the one way “mixed lymphocyte culture” 
(MFC) were not different in patients of both groups; at T1 ( i .e. ,  after treatment) 
“mixed lymphocyte culture” was not significantly modified; the obvious change 
in the serum immunoglobulin profile was observed in the IVIG group. A good 
correlation was observed between the “double tube microinvasion test” and the 
clinical outcome. Only in 3 out of 15 cases tested (4 cases were not assayed 
because cell cultures were lost), the number of trophoblast cells at 3 mm distance 
from the interface out of the total number of trophoblast cells at the interface was 
lower than 5% and, more important, in 2 of these 3 cases an ongoing pregnancy 
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resulted after IVIG treatment. Among the remaining 12 cases, showing a rnicroin- 
vasion greater than 5% at 3 mm, pregnancy was observed only in a single case. 
These findings suggest that those cases in which the trophoblast invasion during 
the test with prepared endometrium is defective may be responsive to an im- 
mune treatment. 
In view of a possible wide application of the “double tube microinvasion 
test” as a prognostic assay for the use of the intravenous immunoglobulin in the 
prevention of implantation failures, and considering the high cost of this treatment, 
it is clear that more studies, either clinically oriented and/or laboratory based, 
are necessary. 
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